clinical trial · NCT07054255
Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects
Haisco Pharmaceutical Group Co., Ltd.·phase1·completed·n = 72
HealthyTest formulation (Ranolazine extended-release tablets)Reference formulation (Ranolazine extended-release tablets)
brief summary
The present study was conducted with the objective of comparing the bioequivalence and safety of a single dose of ranolazine extended-release tablets (Test product) manufactured by Haisco Pharmaceutical Group Co., Ltd. with those of the reference product (Ranexa®, Gilead Sciences, Inc.) in Chinese healthy subjects under fasting and fed conditions
started
Sep 6, 2020
primary completion
Nov 9, 2020
completion
Dec 21, 2020
last updated
Jul 8, 2025
official title
Bioequivalence and Safety Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open-label, Single-dose, Cross-over Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol